Gujarat Kidney & Super Speciality Limited (NSE: GKSL, BSE: 544666) is a Vadodara, Gujarat-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹1,400 Cr, it ranks #1,379 by market cap among the 6,189 Indian listed companies on FinBizNet, and #18 of 42 in Hospitals and Healthcare Centers. At ₹174.95 (as of 28 Oct 2026), the share price is 16.6% below its 52-week high of ₹209.80 and 77.9% above its 52-week low of ₹98.36.
| Current Price | ₹174.95 |
|---|---|
| Market Cap | ₹1,400 Cr |
| NSE Symbol | GKSL |
| BSE Code | 544666 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Facilities > Hospitals and Healthcare Centers |
| P/E Ratio | 71.4 |
| Return on Equity | 6.60% |
| Return on Assets | 7.88% |
| 52-Week Range | ₹98.36 – ₹209.80 |
| 3-Month Price Change | +37.8% |
| Beta (1Y) | 0.46 |
| Headquarters | Vadodara, Gujarat |
| Website | www.gujaratsuperspecialityhospital.com |
| Revenue | ₹34 Cr |
|---|---|
| Net Profit | ₹5 Cr |
| Net Margin | 15.5% |
| EPS (Basic) | ₹0.66 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Gujarat Kidney and Super Speciality Limited operates multi-specialty and super-specialty hospitals. It provides treatment for Oncology, Neurology, Gastroenterology, Urology, Nephrology, and Physiotherapy. It also offers Renal Surgery, Vascular Surgery, Gynecology and obstetrics, Robotic Surgery, Bariatric Surgery, Laparoscopic Surgery, Endocrine Surgery, Neurosurgery, and Joint Replacement services. Its facilities include intensive care unit, patient counselling, operation theatres, and dialysis center. Gujarat Kidney And Super Speciality Limited was founded in 2014 and is headquartered in Vadodara, India.
1. Dealing in Trading of Pharma Goods-This segment operates multi-specialty and super-specialty hospitals. 2. NA-NA 3. NA-NA 4. NA-NA
1. Dealing in Trading of Pharma Goods-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹1,12,785 Cr | 58.1 | 21.50% | ₹7,044 Cr | -2.7% |
| Manipal Health Enterprises Ltd | ₹82,040 Cr | 81.3 | — | ₹3,091 Cr | — |
| Max Healthcare Institute Ltd | ₹81,271 Cr | 56.6 | 14.33% | ₹2,366 Cr | -30.1% |
| Aster Dm Healthcare Limited (Asterdm) | ₹56,321 Cr | 86 | 10.07% | ₹1,311 Cr | -7.9% |
| Fortis Healthcare Ltd. | ₹55,467 Cr | 53.2 | 11.01% | ₹2,545 Cr | -32.6% |
| Global Health Ltd (Medanta) | ₹32,587 Cr | 58.7 | 15.03% | ₹1,304 Cr | -9.0% |
| Krishna Institute Of Medical Science (KIMS) | ₹26,793 Cr | 111 | 9.72% | ₹1,180 Cr | -3.4% |
| Dr. Agarwal's Health Care Limited | ₹15,067 Cr | 113.7 | 8.31% | ₹614 Cr | -12.9% |
| Gujarat Kidney & Super Speciality Limited | ₹1,400 Cr | 71.4 | 6.60% | ₹34 Cr | — |
Listed by market capitalisation. Ratios are shown for context only.
Gujarat Kidney & Super Speciality Limited is trading at ₹174.95, with a market capitalisation of ₹1,400 Cr.
Gujarat Kidney & Super Speciality Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).
Gujarat Kidney & Super Speciality Limited has a P/E of 71.4 and a return on equity of 6.60%.
Gujarat Kidney & Super Speciality Limited is listed on the NSE under the symbol GKSL and on the BSE under the scrip code 544666.
In Q1 FY27, Gujarat Kidney & Super Speciality Limited reported revenue of ₹34 Cr and net profit of ₹5 Cr, with basic EPS of ₹0.66 (consolidated, parsed from the company's exchange filing).
Data as of 28 Oct 2026. Descriptive market data only — not investment advice.